Key Points
- James Peyer, a major shareholder, sold 5,000 shares on Dec. 4 at an average price of $9.06 for $45,300, leaving him with 177,654 shares (a 2.74% reduction), and additionally sold 16,295 shares on Dec. 5 at $11.50 for $187,392.50.
- Sensei Biotherapeutics shares opened at $8.24 and were reported as down 15.2%, with a market cap of $10.38 million, a 12‑month range of $5.00–$18.35, and a negative P/E, highlighting its small‑cap, distressed valuation.
- Analyst sentiment is mixed but averages a "Moderate Buy" with a $55.00 target; the company reported a quarterly EPS of ($3.62) that beat estimates, while analysts forecast about (‑1.17) EPS for the current year.
Sensei Biotherapeutics, Inc. (NASDAQ:SNSE - Get Free Report) major shareholder James Peyer sold 5,000 shares of the firm's stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $9.06, for a total value of $45,300.00. Following the completion of the sale, the insider directly owned 177,654 shares of the company's stock, valued at $1,609,545.24. This trade represents a 2.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Large shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.
James Peyer also recently made the following trade(s):
- On Friday, December 5th, James Peyer sold 16,295 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $11.50, for a total value of $187,392.50.
Sensei Biotherapeutics Stock Down 15.2%
Shares of SNSE opened at $8.24 on Tuesday. The business's fifty day moving average is $9.89 and its 200 day moving average is $8.62. Sensei Biotherapeutics, Inc. has a 12-month low of $5.00 and a 12-month high of $18.35. The stock has a market cap of $10.38 million, a P/E ratio of -0.43 and a beta of 0.32.
Sensei Biotherapeutics (NASDAQ:SNSE - Get Free Report) last announced its quarterly earnings results on Friday, November 14th. The company reported ($3.62) EPS for the quarter, beating analysts' consensus estimates of ($4.11) by $0.49. On average, analysts expect that Sensei Biotherapeutics, Inc. will post -1.17 EPS for the current year.
Wall Street Analysts Forecast Growth
Several research firms have recently commented on SNSE. Weiss Ratings reissued a "sell (e+)" rating on shares of Sensei Biotherapeutics in a research report on Wednesday, November 19th. HC Wainwright lowered Sensei Biotherapeutics from a "buy" rating to a "neutral" rating in a report on Thursday, October 30th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $55.00.
Check Out Our Latest Stock Analysis on SNSE
Sensei Biotherapeutics Company Profile
(
Get Free Report)
Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
